Treviso/Milan, March 14, 2024 –This is what emerged at “Wired Health”, held yesterday, March 13, at BASE in Milan, during the session “3D Printing, Engineering for Healthcare.” According to research by Polaris, the global “3D Bioprinting” market is expected to grow at a CAGR of 15.9% from 2021 to 2030, when it will be worth more than $6.5 billion.
The innovative Electrospider printer has already received orders not only from Italy, but also from Switzerland and the U.S. In fact, it will be one of the main technologies that will be included in the new 3D Printing Laboratory that will start at the Innovation Building, recently opened on the Humanitas University campus.
For SolidWorld Group, the collaboration begun with Humanitas University is a source of satisfaction, a recognition of the highly innovative path the group is taking. Electrospider In fact, Electrospider is capable of reproducing human cells and tissues with additive technology, enabling both the tissue support structure, made of biocompatible material by electrospinning technique with nanometer thickness, and cell hydrogels of different types of human cells to be printed simultaneously for the first time.
“The new 3D laboratory at Humanitas University represents a highly innovative platform where expertise from medicine, cell biology and biomedical engineering intersect. Electrospider is one of the flagship tools of this new technology park and will enable the development of three-dimensional cellular models to support research in the field of personalized medicine” stated Mr. Paolo Oliva, head of the 3D Innovation Lab and Research Technology Management at Humanitas.
***
SolidWorld Group S.p.A. heads a consortium of 11 companies founded in the early 2000s by engineer Roberto Rizzo. Listed on the Euronext Growth Milan segment, the Group is a leader in the development and integration of the most advanced and comprehensive 3D digital technologies, both in software and hardware, within manufacturing companies to support and accelerate their transformation towards Industry 4.0. Thanks to SolidWorld, all stages of a product’s production, from manufacturing to sales and recycling, are integrated through technologies that make the production process faster, more sustainable, and efficient. Operating through 14 locations and 3 technological hubs, it boasts over 150 employees and serves more than 9,000 client companies. In 2023, the group commenced mass production of the Electrospider, a 3D bioprinter capable of replicating human tissues and organs. In the same year, the acquisition of Valore BF 3d S.r.l. was finalized, enabling SolidWorld to expand its client base. Additionally, in 2023, the technological business unit transfer from Formula E S.r.l., a subsidiary of Vismunda S.r.l., a global leader in automation for renewable energy equipment, was completed. In the first half of 2023 SolidWorld Group recorded revenues of €33.1 million, with a production value of approximately €35.2 million and an EBITDA of €2.8 million. The company has been listed on the Euronext Growth Milan segment of Borsa Italiana since July 6, 2022 (with ticker S3D).
www.solidworld.it
Contacts:
IR & Media Advisor TWIN Srl
Maria Di Giorgio
T: +39 3357737417
E-mail: mara@twin.services
Chiara Bortolato
T: +39 3478533894
E-mail:chiara@twin.services
Related topics:
European Small and Mid-Cap awards 2023 SolidWorld Group receives “Star of Innovation” award
Following a careful evaluation by an expert jury, the "Star...
Read more..SolidWorld 3D Bioprinters arrive in Qatar: Five-Year Distribution Agreement Signed with Orion Bostars LLC
The Doha-based Qatar agency will supply SolidWorld’s biomedical products to...
Read more..3D technology, SolidWorld GROUP reproduces a human brain with a tumor in 3D
The subsidiary Bio3DModel 3D printed an exact copy of the...
Read more..